Raymond James & Associates’s West Pharmaceutical WST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $23.3M | Buy |
77,545
+1,709
| +2% | +$523K | 0.01% | 738 |
|
|
2024
Q2 | $25M | Buy |
75,836
+6,256
| +9% | +$2.21M | 0.02% | 663 |
|
|
2024
Q1 | $27.5M | Sell |
69,580
-381
| -0.5% | -$141K | 0.02% | 634 |
|
|
2023
Q4 | $24.6M | Buy |
69,961
+5,564
| +9% | +$1.97M | 0.02% | 643 |
|
|
2023
Q3 | $24.2M | Buy |
64,397
+2,150
| +3% | +$831K | 0.02% | 604 |
|
|
2023
Q2 | $23.8M | Sell |
62,247
-1,095
| -2% | -$391K | 0.02% | 623 |
|
|
2023
Q1 | $21.9M | Buy |
63,342
+5,601
| +10% | +$1.64M | 0.02% | 639 |
|
|
2022
Q4 | $13.6M | Sell |
57,741
-565
| -1% | -$134K | 0.01% | 841 |
|
|
2022
Q3 | $14.3M | Sell |
58,306
-10,304
| -15% | -$3.14M | 0.01% | 763 |
|
|
2022
Q2 | $20.7M | Sell |
68,610
-5,302
| -7% | -$1.73M | 0.02% | 601 |
|
|
2022
Q1 | $30.4M | Buy |
73,912
+1,584
| +2% | +$620K | 0.03% | 525 |
|
|
2021
Q4 | $33.9M | Sell |
72,328
-1,731
| -2% | -$745K | 0.03% | 506 |
|
|
2021
Q3 | $31.4M | Buy |
74,059
+2,071
| +3% | +$873K | 0.03% | 509 |
|
|
2021
Q2 | $25.9M | Sell |
71,988
-812
| -1% | -$268K | 0.02% | 584 |
|
|
2021
Q1 | $20.5M | Buy |
72,800
+15,370
| +27% | +$4.4M | 0.02% | 657 |
|
|
2020
Q4 | $16.3M | Sell |
57,430
-2,422
| -4% | -$680K | 0.02% | 710 |
|
|
2020
Q3 | $16.5M | Buy |
59,852
+9,824
| +20% | +$2.6M | 0.02% | 626 |
|
|
2020
Q2 | $11.4M | Buy |
50,028
+12,170
| +32% | +$2.39M | 0.02% | 762 |
|
|
2020
Q1 | $5.76M | Sell |
37,858
-2,105
| -5% | -$324K | 0.01% | 969 |
|
|
2019
Q4 | $6.01M | Buy |
39,963
+220
| +0.6% | +$32K | 0.01% | 1146 |
|
|
2019
Q3 | $5.64M | Sell |
39,743
-5,739
| -13% | -$790K | 0.01% | 1150 |
|
|
2019
Q2 | $5.69M | Sell |
45,482
-1,201
| -3% | -$142K | 0.01% | 1148 |
|
|
2019
Q1 | $5.14M | Buy |
46,683
+2,169
| +5% | +$226K | 0.01% | 1172 |
|
|
2018
Q4 | $4.36M | Sell |
44,514
-178
| -0.4% | -$19.3K | 0.01% | 1178 |
|
|
2018
Q3 | $5.52M | Sell |
44,692
-21,777
| -33% | -$2.44M | 0.01% | 1158 |
|
|
2018
Q2 | $6.6M | Sell |
66,469
-6,258
| -9% | -$576K | 0.01% | 1030 |
|
|
2018
Q1 | $6.42M | Buy |
72,727
+1,574
| +2% | +$147K | 0.01% | 1007 |
|
|
2017
Q4 | $7.02M | Buy |
71,153
+1,436
| +2% | +$141K | 0.01% | 947 |
|
|
2017
Q3 | $6.71M | Sell |
69,717
-538
| -0.8% | -$48.7K | 0.01% | 938 |
|
|
2017
Q2 | $6.64M | Buy |
70,255
+6,436
| +10% | +$592K | 0.01% | 913 |
|
|
2017
Q1 | $5.21M | Buy |
63,819
+594
| +0.9% | +$49.7K | 0.01% | 1004 |
|
|
2016
Q4 | $5.36M | Buy |
63,225
+1,730
| +3% | +$136K | 0.01% | 952 |
|
|
2016
Q3 | $4.58M | Buy |
61,495
+6,249
| +11% | +$496K | 0.01% | 996 |
|
|
2016
Q2 | $4.19M | Sell |
55,246
-1,139
| -2% | -$82.9K | 0.01% | 949 |
|
|
2016
Q1 | $3.91M | Sell |
56,385
-155
| -0.3% | -$9.33K | 0.01% | 945 |
|
|
2015
Q4 | $3.4M | Buy |
56,540
+4,629
| +9% | +$278K | 0.01% | 996 |
|
|
2015
Q3 | $2.81M | Sell |
51,911
-4,355
| -8% | -$254K | 0.01% | 1036 |
|
|
2015
Q2 | $3.27M | Buy |
56,266
+5,169
| +10% | +$289K | 0.01% | 1045 |
|
|
2015
Q1 | $3.08M | Buy |
51,097
+19,477
| +62% | +$1.04M | 0.01% | 988 |
|
|
2014
Q4 | $1.68M | Buy |
31,620
+14,272
| +82% | +$714K | 0.01% | 1260 |
|
|
2014
Q3 | $776K | Buy |
+17,348
| New | +$737K | ﹤0.01% | 1639 |
|
Other funds holding WST
Raymond James & Associates's WST Position: Q3 2024 in Review
Raymond James & Associates increased its West Pharmaceutical (WST) stake by 2.3% in Q3 2024, buying an estimated $523K and bringing the position to 77,545 shares worth $23.3M. The position accounts for 0.01% of the portfolio, ranked #738.
Raymond James & Associates first reported a position in WST in Q3 2014 and has held it in 41 quarters since. The position peaked at $33.9M in Q4 2021. 730 funds tracked by Wall St. Rank hold WST as of Q3 2024.
- Raymond James & Associates held 77,545 shares of West Pharmaceutical worth $23.3M as of Q3 2024.
- Raymond James & Associates bought 1,709 West Pharmaceutical shares in Q3 2024, an estimated $523K.
- West Pharmaceutical made up 0.01% of Raymond James & Associates's portfolio in Q3 2024, its #738 holding.
- Raymond James & Associates first reported a position in West Pharmaceutical in Q3 2014 and has held it in 41 quarters since.
- Raymond James & Associates's West Pharmaceutical position peaked at $33.9M in Q4 2021.
- 730 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.